IDH1 and central nervous system cancer: On the other hand, the high expression of PD-L1 in most gliomas underscores its potential as a biomarker and therapeutic target, although its effectiveness may vary depending on the presence or absence of an IDH1 (R132H) mutation. The graphic representation (Figure 6) highlights PD-L1 positivity's potential as both a biomarker and a therapeutic target by providing a clear visualization of its prevalence across all glioma samples analyzed.